Clinical Trial Update: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer [Phase 1]

View source ↗

Summary

This update summarizes completion of a Phase 1 trial assessing the safety of larotrectinib in adults with solid tumors harboring NTRK gene fusions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Fusion-positive Solid Tumors

Drugs mentioned

• Larotrectinib (larotrectinib)

Snippet

Sponsor: Bayer | Conditions: Solid Tumors Harboring NTRK Fusion | Phase 1 | Status: COMPLETED